Feasibility of Outpatient Hybrid Brachytherapy for Cervical Cancer with Minimal Sedation: Results from a Single-institutional Protocol

Overview

Journal J Contemp Brachytherapy

Date 2023 Mar 27

PMID 36970442

Authors

Subhakar Mutyala

Gabriella Smith

Hayden Ansinelli

Nitika Thawani

Affiliations

Soon will be listed here.

Abstract

Purpose: Pain control techniques during high-dose-rate hybrid intracavitary-interstitial brachytherapy (HBT) for cervical cancer vary widely, with many centers opting for general anesthesia (GA) or conscious sedation (CS). Here, we describe a single-institutional series of patients treated with HBT and ASA-defined minimal sedation, utilizing oral analgesic and anxiolytic medications in substitution for GA or CS.

Material And Methods: The charts of patients who underwent HBT treatments for cervical cancer from June 2018 to May 2020 were retrospectively reviewed. Prior to HBT, all patients underwent an exam under anesthesia (EUA), and Smit sleeve placement under general anesthesia or deep sedation. Oral lorazepam and oxycodone/acetaminophen were administered between 30-90 minutes before HBT procedure for minimal sedation. HBT placement was performed on computed tomography (CT) table, with needle advancement under CT-guidance.

Results: Treatments with minimal sedation were attempted in 63 patients. A total of 244 interstitial implants with 453 needles were placed via CT-guidance. Sixty-one patients (96.8%) tolerated the procedure without any additional intervention, while two patients (3.2%) required the use of epidural anesthesia. None of the patients in the series required a transition to general anesthesia for the procedure. Bleeding, which resolved with short-term vaginal packing, occurred in 22.1% of insertions.

Conclusions: In our series, the treatment of HBT for cervical cancer with minimal sedation was feasible at a high percentage (96.8%). The ability to perform HBT without GA or CS could be a reasonable option to provide image-guided adaptive brachytherapy (IGABT) with limited resources, allowing for more widespread use. Further investigations using this technique are warranted.

References

Rijkmans E, Nout R, Rutten I, Ketelaars M, Neelis K, Laman M . Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol. 2014; 135(2):231-8. DOI: 10.1016/j.ygyno.2014.08.027. View

Potter R, Tanderup K, Schmid M, Jurgenliemk-Schulz I, Haie-Meder C, Fokdal L . MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021; 22(4):538-547. DOI: 10.1016/S1470-2045(20)30753-1. View

Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout R . Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys. 2014; 89(2):260-7. DOI: 10.1016/j.ijrobp.2014.02.018. View

Nomden C, de Leeuw A, Moerland M, Roesink J, Tersteeg R, Jurgenliemk-Schulz I . Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011; 82(4):1424-30. DOI: 10.1016/j.ijrobp.2011.04.044. View

Bates J, Thaker N, Parekh A, Royce T . Geographic access to brachytherapy services in the United States. Brachytherapy. 2021; 21(1):29-32. DOI: 10.1016/j.brachy.2021.05.004. View

Scanderbeg D, Yashar C, Ouhib Z, Jhingran A, Einck J . Development, implementation, and associated challenges of a new HDR brachytherapy program. Brachytherapy. 2020; 19(6):874-880. PMC: 7495265. DOI: 10.1016/j.brachy.2020.08.018. View

Chargari C, Arbyn M, Leary A, Abu-Rustum N, Basu P, Bray F . Increasing global accessibility to high-level treatments for cervical cancers. Gynecol Oncol. 2021; 164(1):231-241. PMC: 9496636. DOI: 10.1016/j.ygyno.2021.10.073. View

Petitt M, Ackerman R, Hanna M, Chen L, Mhaskar R, Fernandez D . Anesthetic and analgesic methods for gynecologic brachytherapy: A meta-analysis and systematic review. Brachytherapy. 2020; 19(3):328-336. DOI: 10.1016/j.brachy.2020.01.006. View

Sommat K, Lin J, Chew M, Loh C, Liew J, Foo Y . Non-anesthetist-administered moderate sedation with midazolam and fentanyl for outpatient MRI-aided hybrid intracavitary and interstitial brachytherapy in cervix cancer: a single-institution experience. J Contemp Brachytherapy. 2021; 13(3):286-293. PMC: 8170517. DOI: 10.5114/jcb.2021.105946. View

10.

Viswanathan A, Beriwal S, De Los Santos J, Demanes D, Gaffney D, Hansen J . American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012; 11(1):47-52. PMC: 3489267. DOI: 10.1016/j.brachy.2011.07.002. View

11.

Amiri S, Greer M, Muller C, Johansson P, Petras A, Allick C . Disparities in Access to Radiation Therapy by Race and Ethnicity in the United States With Focus on American Indian/Alaska Native People. Value Health. 2022; 25(12):1929-1938. DOI: 10.1016/j.jval.2022.03.025. View

12.

Bhanabhai H, Samant R, E C, Grenier L, Lowry S . Pain assessment during conscious sedation for cervical cancer high-dose-rate brachytherapy. Curr Oncol. 2013; 20(4):e307-10. PMC: 3728059. DOI: 10.3747/co.20.1404. View

13.

Mayadev J, Klapheke A, Yashar C, Hsu I, Kamrava M, Mundt A . Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California. Gynecol Oncol. 2018; 150(1):73-78. DOI: 10.1016/j.ygyno.2018.04.563. View

14.

Bentahila R, Rassy E, Achkar S, Sacino F, Bougas S, Vallard A . Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France. Cancers (Basel). 2022; 14(12). PMC: 9221527. DOI: 10.3390/cancers14122935. View

15.

Potter R, Dimopoulos J, Georg P, Lang S, Waldhausl C, Wachter-Gerstner N . Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007; 83(2):148-55. DOI: 10.1016/j.radonc.2007.04.012. View

16.

Lim K, Lu J, Wynne C, Back M, Mukherjee R, Razvi K . A study of complications arising from different methods of anesthesia used in high-dose-rate brachytherapy for cervical cancer. Am J Clin Oncol. 2004; 27(5):449-51. DOI: 10.1097/01.coc.0000128723.00352.ad. View

17.

Kirisits C, Lang S, Dimopoulos J, Berger D, Georg D, Potter R . The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results. Int J Radiat Oncol Biol Phys. 2006; 65(2):624-30. DOI: 10.1016/j.ijrobp.2006.01.036. View

18.

Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C . Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol. 2012; 103(3):305-13. DOI: 10.1016/j.radonc.2012.04.007. View

19.

Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan L, Gillham C . Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016; 120(3):434-440. DOI: 10.1016/j.radonc.2016.03.020. View

20.

Leong Y, Tan K, Choo B, Koh V, Tang J . Novel anesthetic technique for combined intracavitary and interstitial brachytherapy for cervix cancer in an outpatient setting. J Contemp Brachytherapy. 2017; 9(3):236-241. PMC: 5509986. DOI: 10.5114/jcb.2017.68469. View